Inozyme Pharma (Inozyme Pharma) Cash, Cash Equivalents, Marketable Securities : $166.15 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inozyme Pharma Cash, Cash Equivalents, Marketable Securities?

Inozyme Pharma's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 ($192.44 Mil) to Dec. 2023 ($188.59 Mil) but then stayed the same from Dec. 2023 ($188.59 Mil) to Mar. 2024 ($166.15 Mil).

Inozyme Pharma's annual cash, cash equivalents, marketable securities increased from Dec. 2021 ($111.80 Mil) to Dec. 2022 ($127.87 Mil) and increased from Dec. 2022 ($127.87 Mil) to Dec. 2023 ($188.59 Mil).

Inozyme Pharma Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Inozyme Pharma's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inozyme Pharma Cash, Cash Equivalents, Marketable Securities Chart

Inozyme Pharma Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

47.13

147.70

111.80

127.87

188.59

Inozyme Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															130.93	140.25	192.44	188.59	166.15

Inozyme Pharma Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Inozyme Pharma (NAS:INZY) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Inozyme Pharma Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Inozyme Pharma's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Inozyme Pharma (Inozyme Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inozyme Pharma Inc (NAS:INZY) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

321 Summer Street, Suite 400, Boston, MA, USA, 02210

Website

https://www.inozyme.com

Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.

Executives

Robert Lorne Hopfner	director, 10 percent owner	C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111
Pivotal Bioventure Partners Fund I G.p., L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I U.g.p. Ltd	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Pivotal Bioventure Partners Fund I, L.p.	director	501 SECOND STREET, SUITE 200, SAN FRANCISCO CA 94107
Matthew Winton	officer: COO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Sanjay Subramanian	officer: SVP, CFO	5 GREAT VALLEY PARKWAY, SUITE 160, MALVERN PA 19355
Henric Bjorn Bjarke	officer: See Remarks	ONE UNIVERSITY SQUARE DRIVE, SUITE 280, PRINCETON NJ 08540
Axel Bolte	director, 10 percent owner, officer: See Remarks	PTC THERAPEUTICS, INC., 100 CORPORATE COURT, SOUTH PLAINFIELD NJ 07080
Longitude Capital Partners Iii, Llc	10 percent owner	800 EL CAMINO, SUITE 220, MENLO PARK CA 94025
Inozyme Pharma, Inc.	director	321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Stephen J. Dipalma	officer: Interim CFO	C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139
Deborah Wenkert	officer: SVP, CMO	C/O INOZYME PHARMA, INC., 321 SUMMER STREET, SUITE 400, BOSTON MA 02210
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Scott D Sandell	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025